

REQUIRED ITEMS

- 1. Pathology Report
- 2. Clinical Information
- 3. Face Sheet (Front and Back Copy of the Patient's Insurance Card and Demographic Information)
- 4. Provider's Signature
- 5. Name of Person Who Completed Requisition Form

PATIENT INFORMATION

Last Name _____
 First Name _____ M.I. _____
 DOB ____/____/____ Gender: Male Female Other _____
 Address _____
 City _____ State _____ Zip _____
 Phone _____ Patient ID _____

PROVIDER INFORMATION

The undersigned certifies by completion of this section, that he/she is authorized to order the test(s) listed below and that such test(s) are medically necessary for the care and/or treatment of this patient.

Authorized Provider Signature _____ Date ____/____/____
 Please Fax Duplicate Report to Additional Provider _____ Fax ____/____/____

BILLING INFORMATION

Bill to: Insurance Medicare Referring Facility (Hospital/Client) Split Billing - Client (TC) and Insurance (PC) Patient
 Patient Status: Inpatient (Hospital) Outpatient (Hospital) Non-Hospital ASC Prior Authorization # _____

CLINICAL INFORMATION

Indication(s) for Testing: _____
 ICD-10 Codes: _____
 Disease: New Diagnosis Refractory Recurrent/Relapsed Follow-Up (Monitoring) Metastatic

SPECIMEN INFORMATION

Copy of pathology report provided Time Collected ____:____:____ AM PM
 Date Collected ____/____/____ Specimen ID _____
 Specimen Site _____
 Date Retrieved ____/____/____ Date Discharged ____/____/____
 UNSTAINED SLIDES, # of Slides _____ Slide Thickness _____ H&E
 SPECIMEN PICK UP: I would like CorePath to request the block(s) from the facility.
 Facility Name _____ Phone _____ Fax _____
 Address _____ City _____ State _____ Zip _____

TEST REQUESTED (FOR MORE TESTING INFORMATION, VISIT COREPATH.US)

20/20 TumorCORE EVALUATION REPORT
 Request that CorePath's Board Certified Pathologists review the patient's pathology report along with their clinical history and all materials submitted with this order to select the medically necessary tests for a comprehensive analysis and efficient patient care with the end goal of timely guidance for treatment, staging, prognosis and risk stratification by the treating providers. This includes any assays/panels as outlined here, if clinically indicated.

TYPES OF TUMOR

<input type="checkbox"/> Biliary/Pancreatic	<input type="checkbox"/> Colorectal	<input type="checkbox"/> Gynecologic	<input type="checkbox"/> Prostate	<input type="checkbox"/> Unknown Primary
<input type="checkbox"/> Bladder (Urinary)	<input type="checkbox"/> Esophageal	<input type="checkbox"/> Head/Neck	<input type="checkbox"/> Renal	<input type="checkbox"/> Other: _____
<input type="checkbox"/> Brain	<input type="checkbox"/> Gastric	<input type="checkbox"/> Hepatocellular	<input type="checkbox"/> Salivary Glands	
<input type="checkbox"/> Bone	<input type="checkbox"/> Genitourinary	<input type="checkbox"/> Lung	<input type="checkbox"/> Soft Tissue Sarcomas	
<input type="checkbox"/> Breast	<input type="checkbox"/> GIST	<input type="checkbox"/> Melanoma (Metastatic)	<input type="checkbox"/> Thyroid	

NEXT GENERATION SEQUENCING (NGS) PROFILES (BLOCKS/SLIDES)
 CORE Solid Tumor Expression Profile (DNA and RNA)

NEXT GENERATION SEQUENCING (NGS) PROFILES (LIQUID BIOPSY)
 CORE Liquid Biopsy Solid Tumor Profile (DNA and RNA)*
 *2 EDTA Tubes, Peripheral Blood Only

MOLECULAR ASSAYS

<input type="checkbox"/> KRAS/NRAS/BRAF Mutation	<input type="checkbox"/> MGMT Promoter Methylation	<input type="checkbox"/> TERT Promoter Methylation
<input type="checkbox"/> BRAF V600E Mutation	<input type="checkbox"/> Microsatellite Instability (MSI) Analysis	<input type="checkbox"/> TP53 Mutation
<input type="checkbox"/> EGFR Mutation	<input type="checkbox"/> MLH1 Promoter Methylation	<input type="checkbox"/> Other: _____
<input type="checkbox"/> IDH1/IDH2 Mutation	<input type="checkbox"/> OncotypeDX®	
<input type="checkbox"/> KIT Mutation	<input type="checkbox"/> Breast <input type="checkbox"/> Prostate <input type="checkbox"/> Colon	
<input type="checkbox"/> KRAS Mutation	<input type="checkbox"/> PDGFRA Mutation	
<input type="checkbox"/> MET Exon 14 Deletion	<input type="checkbox"/> PIK3CA Mutation	

IMMUNOHISTOCHEMISTRY Please select service: Global TC

<input type="checkbox"/> ER/PR/HER2/Ki-67	<input type="checkbox"/> HER2 (Breast)
<input type="checkbox"/> MMR (MLH1, MSH2, MSH6, PMS2)	<input type="checkbox"/> HER2 (Gastric)
<input type="checkbox"/> TP53	<input type="checkbox"/> HER2 (Other): _____
<input type="checkbox"/> P16	<input type="checkbox"/> Other: _____

OTHER INSTRUCTIONS
 Requisition Completed by _____
LABORATORY USE ONLY

PD-L1 Please select service: Global TC
 PD-L1 22C3 (for KEYTRUDA®) Please specify cancer type: _____
 PD-L1 SP142 (for TECENTRIQ®) Please specify cancer type: _____
 PD-L1 28-8 (for OPDIVO®) Please specify cancer type: _____
 PD-L1 SP263 (for IMFINZI®, LIBTAYO® and TECENTRIQ®) Please specify cancer type: _____
 Other: _____

FISH Please select service: Global TC
 ALK Rearrangement
 DDI3 (12q13) Rearrangement
 EGFR Amplification
 ERG Rearrangement
 EWSR1 (22q12) Rearrangement
 FGFR1 Amplification
 FOXO1 (13q16) Rearrangement
 HER2 Amplification
 MDM2 Amplification
 MET Amplification
 MYCN Amplification
 PTEN Deletion
 ROS1 Rearrangement
 SS18 (SYT) (18q11) Rearrangement
 UroVysion™
 Other: _____

REQUIRED ITEMS

1. Pathology Report 2. Clinical Information 3. Face Sheet (Front and Back Copy of the Patient's Insurance Card and Demographic Information) 4. Provider's Signature 5. Name of Person Who Completed Requisition Form

PREFERRED SPECIMEN REQUIREMENTS

Specimen Type	Bone Marrow Morphology	Flow Cytometry	Routine Chromosome Analysis ¹	FISH ¹	PCR ¹	NGS	IHC/Immunostains
Peripheral Blood ²	Two (2) smears/slides	2 mL sodium heparin ⁴ or EDTA ³	5 mL sodium heparin ⁴ preferred, EDTA ³ acceptable	5 mL sodium heparin ⁴ preferred, EDTA ³ acceptable	4 mL EDTA ³	5 mL EDTA ³ Liquid Biopsy: 10 mL minimum EDTA ³ or 30-50 ng/μl DNA/RNA in microfuge tube	N/A
Bone Marrow Aspirate	Five (5) smears/slides	2 mL EDTA ³ preferred, sodium heparin ⁴ acceptable	1-2 mL sodium heparin ⁴ preferred, EDTA ³ acceptable	1-2 mL sodium heparin ⁴ preferred, EDTA ³ acceptable	2 mL EDTA ³	2 mL EDTA ³	N/A
Bone Marrow Clot	2 mL clot (volume) in 10% NBF*. Two (2) touch prints.	N/A					N/A
Bone Marrow Core Biopsy & Touch Imprints	1 cm core (length) in 10% NBF*. Five (5) touch prints.	1-2 cm core (length) in RPMI	1-2 cm core (length) in RPMI	0.5 cm core (length) in RPMI	1-2 cm core (length) in RPMI	1-2 cm core (length) in RPMI	N/A
Lymph Node/Tissue (Fresh)	N/A	0.5 cm ³ in RPMI. Other fixatives not acceptable.			0.5 cm ³ in RNA fixative or 10% NBF*	0.5 cm ³ tissue in normal saline	FFPE tissue block preferred. 0.5 cm ³ in 10% NBF*.
Formalin Fixed Paraffin Embedded (FFPE) Block or Cut Slides	N/A	N/A	N/A	FFPE tissue block preferred. One (1) H&E stained slide and five (5) unstained slides.	FFPE tissue block preferred ⁵ . One (1) H&E stained slide and five (5) unstained slides.	One (1) H&E stained slide and six (6) to eight (8) unstained slides.	Four (4) to five (5) micron thick tissue sections on positively charged slides. Provide at least three (3) slides per requested antibody.
Fine Needle Aspirate (FNA)	N/A	RPMI				RPMI/Cell block	Cell block
Body Fluids	N/A	CSF: 5 mL in sterile container Pleural: 20 mL in ratio of 1 mL sodium heparin or ACD to 100 mL fluid				5 mL fluid/Cell block	Cell block

*NBF = Neutral Buffered Formalin

¹ Decalcified samples not acceptable | ² Please provide copy of CBC if available | ³ EDTA = Lavender Top | ⁴ Sodium Heparin = Green Top | ⁵ Only for some tests; contact us for details or go to www.corepath.us

TEST NOTATIONS

 IMFINZI® is a registered trademark of the AstraZeneca group of companies.
 KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co.
 LIBTAYO® is a registered trademark of Sanofi Biotechnology.

 OncotypeDX® is a registered trademark of Exact Sciences Corporation.
 OPDIVO® is a registered trademark of Bristol-Myers Squibb Company.
 TECENTRIQ® is a registered trademark of Genentech, a member of the Roche Group.
 UroVysion™ is a registered trademark of Abbott Laboratories.

SPECIMEN HANDLING AND TRANSPORTATION
Storage & Transport: Specimens should be received at CorePath within 72 hours from collection to ensure sample integrity and acceptable cell viability. Ship same day as drawn whenever possible. Peripheral blood and bone marrow should be shipped at room temperature. In hot weather, use cold pack for transport, making sure cold pack is not in direct contact with specimen. Body fluids and tissue should be shipped at 4°C.

Schedule a Pick-Up: Call CorePath Laboratories at 1.877.617.4445 to schedule a pick-up. In the San Antonio area, call 210.617.4445 to schedule a courier pick-up.

© 2024 CorePath Laboratories. All rights reserved.

**FOR MORE INFORMATION ON TESTING,
VISIT WWW.COREPATH.US**